Nuvation Bio (NUVB) stock price is $4.78, up 6.59% on the day, as of Oct 20, 2026. It has a market cap of $1.67Bn, and is classified in the Pharmaceuticals industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap1.67 Bn
P/E-11.13
P/S9.81
Div. Yield0.00
Total Debt (Qtr)5.89 Mn
Revenue Growth (1y) (Qtr)555.64
Add ratio to table…
About
Nuvation Bio Inc. operates as a global oncology enterprise dedicated to developing therapies for significant unmet medical needs in cancer treatment. The company was founded in 2018 by David Hung M. D. who previously established Medivation and directed the creation of Xtandi and talazoparib resulting in Pfizer's acquisition of that company for 14.3 billion dollars in 2016. Nuvation Bio leverages its team's extensive background in medicinal chemistry preclinical development…
Nuvation Bio Inc. operates as a global oncology enterprise dedicated to developing therapies for significant unmet medical needs in cancer treatment. The company was founded in 2018 by David Hung M. D. who previously established Medivation and directed the creation of Xtandi and talazoparib resulting in Pfizer's acquisition of that company for 14.3 billion dollars in 2016. Nuvation Bio leverages its team's extensive background in medicinal chemistry preclinical development drug formulation business strategy and commercial execution to pursue scientifically validated cancer targets. Its methodology centers on targets where initial therapeutic progress exists but where current options possess notable limitations in effectiveness or safety profile. The organization designs novel small molecule compounds intended to deliver superior clinical outcomes through enhanced target engagement and improved pharmacological characteristics. Key assets in its pipeline consist of IBTROZI approved for ROS1 positive non small cell lung cancer and safusidenib under investigation for mutant isocitrate dehydrogenase 1 driven glioma in addition to exploratory compounds generated via its drug drug conjugate technological framework.
Nuvation Bio derives its income chiefly from the sales and licensing of its oncology therapeutic candidates. The company secured United States Food and Drug Administration approval for IBTROZI on June 11 2025 for the treatment of adult patients with locally advanced or metastatic ROS1 positive non small cell lung cancer and commenced commercial distribution in the United States during June 2025. Revenue is generated through direct product sales in the United States market alongside strategic collaboration agreements that provide access to international territories. Under these arrangements Nuvation Bio has obtained substantial upfront payments and milestone achievements from partners including Innovent Biologics for Greater China Nippon Kayaku for Japan and Eisai for Europe and additional global regions. Additional financial contributions come from tiered royalty structures based on net sales of its products within each partner's designated territory. The organization also anticipates future revenue from advancing its clinical programs such as the ongoing development of safusidenib for specific glioma subtypes through partnership with Daiichi Sankyo. Furthermore Nuvation Bio continues to invest in its preclinical drug drug conjugate platform which aims to create novel therapeutic combinations by linking targeting moieties with established anticancer warheads.
Nuvation Bio functions within the highly competitive field of cancer drug development where it contends with both large pharmaceutical enterprises and specialized biotechnology firms. For its primary commercial asset IBTROZI the company encounters direct competition from established tyrosine kinase inhibitors such as Pfizer's Xalkori Roche's Rozlytrek and Bristol Myers Squibb's Augtyro which are currently approved for ROS1 positive non small cell lung cancer. Furthermore emerging alternatives like Nuvalent's zidesamtinib are undergoing clinical evaluation for the same indication. In the realm of its preclinical candidate safusidenib potential future rivals include Servier's Voranigo for isocitrate dehydrogenase mutant glioma and Rigel's olutasidenib which is also in clinical development for similar applications. Nuvation Bio asserts competitive advantages through its leadership team's proven history in bringing oncology medicines to market its rigorous selection of targets supported by robust scientific data and its specialized capability in medicinal chemistry to engineer molecules with advantageous therapeutic indices. The company also emphasizes its agility in forming strategic alliances and its focus on overcoming specific deficiencies of incumbent treatments as key elements of its market approach.
Nuvation Bio serves the global population of individuals diagnosed with specific oncology conditions particularly those harboring ROS1 gene rearrangements in non small cell lung cancer or specific mutations in isocitrate dehydrogenase within glioma cases. The company has established definitive commercial partnerships to facilitate patient access to its therapies across different geographical areas. These collaborations include Innovent Biologics which holds exclusive rights to commercialize taletrectinib the active ingredient in IBTROZI within mainland China Hong Kong Macau and Taiwan. Nippon Kayaku Co., Ltd possesses equivalent rights for the Japanese market while Eisai has secured licensing privileges for the European Union the United Kingdom Switzerland and numerous additional international territories. Beyond these named entities Nuvation Bio engages with healthcare systems medical institutions and prescription networks to ensure its treatments reach eligible patients. The organization provides supplementary resources such as patient support programs to assist with treatment access and affordability for those prescribed its approved medications. Nuvation Bio also maintains active communication channels with advocacy groups and medical societies to enhance disease awareness and support community education initiatives related to its therapeutic areas.
Sector:HealthcareSector rationaleNuvation Bio is a biotechnology company that designs and manufactures oncology therapies, such as IBTROZI for non-small cell lung cancer and safusidenib for glioma. Its revenue is derived from the direct sale of these pharmaceutical products and licensing agreements with other pharmaceutical firms.Industries:PharmaceuticalsPharmaceuticalsPrimaryNuvation Bio develops and markets branded prescription oncology drugs, specifically the FDA-approved IBTROZI for ROS1 positive non small cell lung cancer. Its revenue is generated through direct product sales in the US and licensing/royalties from partners like Eisai and Nippon Kayaku.BiotechnologyBiotechnologySecondaryThe company operates a drug-drug conjugate technological framework and develops therapies like safusidenib, utilizing biotechnology-based research and development for its oncology pipeline.Classified using BQ-MICSCIK: 0001811063
Bull & bear
Investment Thesis
▲ Bull case
Nuvation Bio Inc. is positioned for substantial long-term revenue growth driven by the accelerating shift of Iptrozy (taletrectinib) into the first-line treatment setting for ROS1-positive NSCLC, where its exceptional durability creates a powerful revenue stacking effect. Management highlighted that over 50% of new patient starts in Q1 FY26 were TKI-naive, up from approximately 30% in the first full quarter post-launch, reflecting successful commercial execution and growing physician confidence in Iptrozy’s profile. This shift is critical because first-line patients exhibit significantly longer treatment duration—median duration of response and progression-free survival now exceed 50 months (over four years) based on updated TRUST-I data—compared to later-line patients who discontinue quickly due to disease progression. As later-line patients drop off rapidly, the accumulating base of durable first-line patients will drive net product revenue growth even with stable new patient starts, as evidenced by the 18% quarter-over-quarter increase in Iptrozy net U.S. product revenue to $18.5 million despite only ~200 new starts. This revenue stacking dynamic, which management noted will eventually replace new patient starts as the key metric, is underappreciated by the market and supports consensus net revenue estimates for 2026 while laying the foundation for multi-year growth beyond.
The company’s strategic expansion into adjacent high-value oncology markets through safusidenib (IDH1 inhibitor) and its drug-drug conjugate (DDC) platform provides meaningful diversification and long-term value creation beyond Iptrozy, with near-term catalysts that could re-rating the stock. Nuvation Bio recently secured exclusive global rights to safusidenib from Daiichi Sankyo, including Japan, and plans to expand the pivotal Phase 3 SIGMA study into Japan while advancing global development. Early-phase data show durable responses across all IDH1-mutant glioma subgroups, addressing a significant unmet need where vorasidenib is only approved for low-grade low-risk tumors. Additionally, the DDC platform remains on track for an update by year-end, representing a novel approach to solid tumors. These pipeline advances are bolstered by strong financial flexibility: $533.7 million in cash, cash equivalents, and marketable securities as of March 31, 2026, plus expected milestone payments including ~$30 million from Eisai upon European approval of Iptrozy in 2027. The recent $250 million convertible note offering (increased from $200 million) further strengthens the balance sheet, with net proceeds earmarked for debt repayment, capped call transactions, and general corporate purposes—reducing near-term financing risk while enabling pipeline investment. This combination of near-term liquidity, de-risked commercial execution in ROS1, and undervalued pipeline optionality presents a compelling bullish case the market is overlooking.
Nuvation Bio Inc. is positioned for substantial long-term revenue growth driven by the accelerating shift of Iptrozy (taletrectinib) into the first-line treatment setting for ROS1-positive NSCLC, where its exceptional durability creates a powerful revenue stacking effect. Management highlighted that over 50% of new patient starts in Q1 FY26 were TKI-naive, up from approximately 30% in the first full quarter post-launch, reflecting successful commercial execution and growing physician confidence in Iptrozy’s profile. This shift is critical because first-line patients exhibit significantly longer treatment duration—median duration of response and progression-free survival now exceed 50 months (over four years) based on updated TRUST-I data—compared to later-line patients who discontinue quickly due to disease progression. As later-line patients drop off rapidly, the accumulating base of durable first-line patients will drive net product revenue growth even with stable new patient starts, as evidenced by the 18% quarter-over-quarter increase in Iptrozy net U.S. product revenue to $18.5 million despite only ~200 new starts. This revenue stacking dynamic, which management noted will eventually replace new patient starts as the key metric, is underappreciated by the market and supports consensus net revenue estimates for 2026 while laying the foundation for multi-year growth beyond.
The company’s strategic expansion into adjacent high-value oncology markets through safusidenib (IDH1 inhibitor) and its drug-drug conjugate (DDC) platform provides meaningful diversification and long-term value creation beyond Iptrozy, with near-term catalysts that could re-rating the stock. Nuvation Bio recently secured exclusive global rights to safusidenib from Daiichi Sankyo, including Japan, and plans to expand the pivotal Phase 3 SIGMA study into Japan while advancing global development. Early-phase data show durable responses across all IDH1-mutant glioma subgroups, addressing a significant unmet need where vorasidenib is only approved for low-grade low-risk tumors. Additionally, the DDC platform remains on track for an update by year-end, representing a novel approach to solid tumors. These pipeline advances are bolstered by strong financial flexibility: $533.7 million in cash, cash equivalents, and marketable securities as of March 31, 2026, plus expected milestone payments including ~$30 million from Eisai upon European approval of Iptrozy in 2027. The recent $250 million convertible note offering (increased from $200 million) further strengthens the balance sheet, with net proceeds earmarked for debt repayment, capped call transactions, and general corporate purposes—reducing near-term financing risk while enabling pipeline investment. This combination of near-term liquidity, de-risked commercial execution in ROS1, and undervalued pipeline optionality presents a compelling bullish case the market is overlooking.
Nuvation Bio Inc. faces significant near-term revenue headwinds due to the inherent limitations of its ROS1-positive NSCLC market and the misleading stability in new patient starts, which masks a deteriorating underlying demand trend that could impede long-term growth. Despite management’s emphasis on the shift toward first-line use, the total number of new Iptrozy patient starts has plateaued at approximately 200 per quarter for three consecutive quarters, indicating that the company may be exhausting the finite pool of previously diagnosed later-line patients without sufficient replacement from new diagnoses. This dynamic is exacerbated by persistently low community testing rates—remaining below 50% in some centers—which limit the identification of new ROS1-positive patients, particularly in community settings where most lung cancer care occurs. While academic centers show higher testing and adoption, the community remains a critical bottleneck, and initiatives to improve testing rates face structural hurdles including lack of awareness, reimbursement complexity, and fragmented infrastructure that cannot be quickly overcome. As a result, the growing proportion of first-line starts is not reflecting expanding demand but rather a cannibalization of the later-line pool, meaning revenue growth from stacking may be temporary and insufficient to offset the eventual decline in new patient inflow without a breakthrough in community diagnostics.
The company’s financial profile and capital allocation strategy introduce substantial risks that are being overlooked, particularly the dilution and debt burden from its recent convertible note offering, which could undermine shareholder value despite the strong cash balance. Nuvation Bio issued $250 million in 0.75% Convertible Senior Notes due 2032, with an initial conversion price of ~$7.84 representing a 35% premium to the June 25, 2026 stock price, but the accompanying capped call transactions only cap dilution at a share price of ~$10.46 (80% premium), leaving significant exposure to dilution if the stock appreciates beyond that level. Furthermore, while management states the net proceeds (~$241.2 million) will repay the senior secured loan agreement, the long-term debt remains high at ~$199.2 million ($151.9M non-current + $47.3M long-term borrowings) even after potential repayment, and the notes introduce interest obligations and complex conversion mechanics that could pressure the stock. Concurrently, operating expenses remain elevated at $73.5 million in Q1 FY26, with SG&A at $38.3 million driven by commercialization, and R&D at $35.0 million fueled by SIGMA and TRUST trials—raising concerns about cash burn sustainability if Iptrozy revenue growth slows or pipeline delays occur. These financial risks, combined with the niche nature of the ROS1 market (estimated 3,000–4,000 U.S. patients annually) and reliance on a single approved product, suggest the market may be overestimating the scalability and durability of Nuvation Bio’s near-term prospects.
Nuvation Bio Inc. faces significant near-term revenue headwinds due to the inherent limitations of its ROS1-positive NSCLC market and the misleading stability in new patient starts, which masks a deteriorating underlying demand trend that could impede long-term growth. Despite management’s emphasis on the shift toward first-line use, the total number of new Iptrozy patient starts has plateaued at approximately 200 per quarter for three consecutive quarters, indicating that the company may be exhausting the finite pool of previously diagnosed later-line patients without sufficient replacement from new diagnoses. This dynamic is exacerbated by persistently low community testing rates—remaining below 50% in some centers—which limit the identification of new ROS1-positive patients, particularly in community settings where most lung cancer care occurs. While academic centers show higher testing and adoption, the community remains a critical bottleneck, and initiatives to improve testing rates face structural hurdles including lack of awareness, reimbursement complexity, and fragmented infrastructure that cannot be quickly overcome. As a result, the growing proportion of first-line starts is not reflecting expanding demand but rather a cannibalization of the later-line pool, meaning revenue growth from stacking may be temporary and insufficient to offset the eventual decline in new patient inflow without a breakthrough in community diagnostics.
The company’s financial profile and capital allocation strategy introduce substantial risks that are being overlooked, particularly the dilution and debt burden from its recent convertible note offering, which could undermine shareholder value despite the strong cash balance. Nuvation Bio issued $250 million in 0.75% Convertible Senior Notes due 2032, with an initial conversion price of ~$7.84 representing a 35% premium to the June 25, 2026 stock price, but the accompanying capped call transactions only cap dilution at a share price of ~$10.46 (80% premium), leaving significant exposure to dilution if the stock appreciates beyond that level. Furthermore, while management states the net proceeds (~$241.2 million) will repay the senior secured loan agreement, the long-term debt remains high at ~$199.2 million ($151.9M non-current + $47.3M long-term borrowings) even after potential repayment, and the notes introduce interest obligations and complex conversion mechanics that could pressure the stock. Concurrently, operating expenses remain elevated at $73.5 million in Q1 FY26, with SG&A at $38.3 million driven by commercialization, and R&D at $35.0 million fueled by SIGMA and TRUST trials—raising concerns about cash burn sustainability if Iptrozy revenue growth slows or pipeline delays occur. These financial risks, combined with the niche nature of the ROS1 market (estimated 3,000–4,000 U.S. patients annually) and reliance on a single approved product, suggest the market may be overestimating the scalability and durability of Nuvation Bio’s near-term prospects.